Restasis (Dry Eye Syndrome) ' Analysis and Forecasts to 2022

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Restasis (Dry Eye Syndrome) ' Analysis and Forecasts to 2022
Published on June 2012

Report Summary


Summary

GlobalData's pharmaceuticals report, 'Restasis (Dry Eye Syndrome) ' Analysis and Forecasts to 2022' provides Restasis sales
forecasts for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive
landscape, and analysis of sales performance during the forecast period (2012-2022). The report also includes information on Dry
Eye Syndrome. This report is built using data and information sourced from GlobalData's proprietary databases, primary and
secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from
company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US and EU5.
- Analysis and review of Restasis including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of RestasisLiquid including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2012-2022 for Restasis in the US and EU5

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in six major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2012-2022 for all six major markets

Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 4
2.1 Dry Eye Syndrome 4
2.1.1 Symptoms 4

Restasis (Dry Eye Syndrome) ' Analysis and Forecasts to 2022 (From Slideshare) Page 1/6


2.2 Dry Eye Syndrome Market 5
2.3 Epidemiology 5
2.4 The Main Recognized Risk Factors 6
2.4.1 Patient Related Factors 6
2.4.2 Environmental Factors 7
2.4.3 Occupational Factors 7
2.4.4 Nutritional Factors 7
2.4.5 Systemic Medications 7
2.4.6 Topical Ophthalmic Medications 7
2.4.7 Other Factors 7
2.5 GlobalData Report Guidance 8
3 Dry Eye Syndrome: Market Characterization 9
3.1 Dry Eye Syndrome Market 9
3.2 Dry Eye Syndrome Market Forecasts and CAGR 10
3.3 Drivers and Barriers of Dry Eye Syndrome Therapeutics Market 10
3.3.1 Ageing Population 10
3.3.2 Changing lifestyle 10
3.3.3 High Unmet Need 11
3.3.4 New Product Launches 11
4 Classification of Dry Eye Syndrome 12
4.1 Classification based on Severity Grading Scheme 12
4.2 Classification based on Signs and Symptoms 12
4.2.1 Mild Dry Eye 12
4.2.2 Moderate Dry Eye 12
4.2.3 Severe Dry Eye 12
5 Treatment for Dry Eye Syndrome 13
5.1 Pharmacological Treatment 13
5.1.1 Tear Supplements 13
5.1.2 Anti-inflammatory Agents 14
5.1.3 Mucolytics 14
5.1.4 Autologous Serum 14
5.1.5 Secretagogues and Mucin Enhancing Agents 15
5.1.6 Fatty Acid Supplements 15
5.1.7 Antibiotics 15
5.1.8 Hormonal Therapy 15
5.2 Surgical Interventions 15
5.2.1 Punctal Occlusion Surgery 15
5.2.2 Salivary Gland Autotransplantation 15
5.3 Non Surgical Interventions 15
6 Restasis 16
6.1 Introduction 16
6.2 Mechanism of Action 16
6.3 Clinical Studies 16
6.3.1 Study 001 16
6.3.2 Study 002 17
6.3.3 Study 003 17
6.3.4 Study 501 17
6.3.5 Pooled analysis of studies 002, 003, 501 17



6.4 Approval History of Restasis 17
6.5 Factors Affecting Sales of Restasis 18
6.5.1 Only Drug Approved for Dry Eye Syndrome 18
6.5.2 Approval in Europe 18
6.5.3 Approval New Cyclosporine Products 18
6.5.4 Patent Expiry of Restasis 18
6.5.5 Strong Pipeline for Dry Eye Syndrome 18
6.6 Drug Evaluation 19
6.6.1 Drug Risk Benefit Score 19
6.6.2 Intensity of Competition 20
6.7 Sales Forecasts 20
6.7.1 Target Patient Pool for Restasis 20
6.7.2 Dosing 20
6.7.3 Market Penetration 20
6.7.4 Annual Cost of Therapy 21
6.7.5 Global Sales Projections of Restasis 22
7 Dry Eye Syndrome Market: Appendix 30
7.1 Market Definitions 30
7.2 List of Abberiviations 30
7.3 Research Methodology 30
7.3.1 Coverage 30
7.3.2 Secondary Research 31
7.3.3 Forecasting 31
7.3.4 Number of Patients Approved to Take the Drug 31
7.3.5 Net Penetration of Drug 31
7.3.6 Net Annual Dosing 32
7.3.7 Annual Cost of Therapy 32
7.4 Drug Sales Estimates Model 32
7.5 Contact Us 32
7.6 Disclaimer 32
7.7 Sources 33

List of Tables

Table 1: Dry Eye Syndrome, Global, Major Marketed Products 9
Table 2: Dry Eye Syndrome, Global, Major Pipeline Products in Phase III 9
Table 3: Dry Eye Syndrome ' Severity Grading Scheme 12
Table 4: Restasis, Dry Eye Syndrome, Phase III, Clinical Trial Results 17
Table 5: Restasis, Approval History 17
Table 6: Drug Risk Benefit Score of Restasis 19
Table 7: Annual Cost of Therapy of Restasis 21
Table 8: Restasis, Dry Eye Syndrome, Global, Sales Estimation ($m), 2003'2022 22
Table 9: Restasis, Dry Eye Syndrome, The US, Sales Estimates ($m) , 2002-2022 23
Table 10: Restasis, Dry Eye Syndrome, The UK, Sales Estimates ($m) , 2014-2022 24
Table 11: Restasis, Dry Eye Syndrome, France, Sales Estimates ($m) , 2014-2022 25
Table 12: Restasis, Dry Eye Syndrome, Germany, Sales Estimates ($m) , 2014-2022 26
Table 13: Restasis, Dry Eye Syndrome, Italy, Sales Estimates ($m) , 2014-2022 27
Table 14: Restasis, Dry Eye Syndrome, Spain, Sales Estimates ($m) , 2014-2022 28



List of Figures

Figure 1: Normal Eye and Dry Eye 4
Figure 2: Cascade of Events Leading to Dry Eye 5
Figure 3: Age -standardized prevalence ratio in the US men and women 6
Figure 4: Dry Eye Syndrome, Global, Market Size Forecasts ($bn), 2011'2022 10
Figure 5: Therapeutic Choice for Dry Eye Syndrome 13
Figure 6: Drug Model Diagram of Restasis 20
Figure 7: Restasis, Dry Eye Syndrome, Global, Sales Forecasts ($m), 2003'2022 22
Figure 8: Restasis, Dry Eye Syndrome, The US, Sales Forecasts ($m), 2003'2022 23
Figure 9: Restasis, Dry Eye Syndrome, The UK, Sales Forecasts ($m), 2014'2022 24
Figure 10: Restasis, Dry Eye Syndrome, France, Sales Forecasts ($m), 2014'2022 25
Figure 11: Restasis, Dry Eye Syndrome, Germany, Sales Forecasts ($m), 2014'2022 26
Figure 12: Restasis, Dry Eye Syndrome, Italy, Sales Forecasts ($m), 2014'2022 27
Figure 13: Restasis, Dry Eye Syndrome, Spain, Sales Forecasts ($m), 2014'2022 28
Figure 14: Restasis, Global, Sales Distribution by Country (%), 2022 29
Figure 15: Patients Approved for the Drug 31


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Restasis (Dry Eye Syndrome) ' Analysis and Forecasts to 2022

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Restasis (Dry Eye Syndrome) ' Analysis and Forecasts to 2022